Grant enables the further development of Cantabios innovative DJ1 replacement therapy, which have high therapeutic potential in both diseasemodifying and preventive contexts for the treatment of Parkinsons disease.SAN MATEO, CA / ACCESSWIRE / February 6, 2024 / Cantabio Pharmaceuticals, Inc. "Cantabio" or the "Company", a preclinical stage pharmaceutical company developing... Lire le communiqué |